Get the Stockscreener App
43.90
0.50%
0.22
After Hours:
44.77
0.87
+1.98%
Corcept Therapeutics Inc stock is traded at $43.90, with a volume of 840.68K.
It is up +0.50% in the last 24 hours and up +36.55% over the past month.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
See More
Previous Close:
$43.68
Open:
$43.76
24h Volume:
840.68K
Relative Volume:
0.44
Market Cap:
$4.67B
Revenue:
$761.41M
Net Income/Loss:
$98.16M
P/E Ratio:
53.66
EPS:
0.8181
Net Cash Flow:
$141.79M
1W Performance:
+4.85%
1M Performance:
+36.55%
6M Performance:
-42.85%
1Y Performance:
-36.92%
1-Day Range:
$43.27
$44.42
1-Week Range:
$41.00
$44.42
52-Week Range:
$28.66
$91.00
Corcept Therapeutics Inc Stock (CORT) Company Profile
Name
Corcept Therapeutics Inc
Sector
Industry
Phone
650.688.8803
Address
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Compare CORT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
43.90 | 4.65B | 761.41M | 98.16M | 141.79M | 0.8181 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-26-26 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Dec-31-25 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Dec-16-25 | Initiated | UBS | Neutral |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Nov-06-23 | Upgrade | Truist | Hold → Buy |
| Apr-11-23 | Initiated | SVB Securities | Market Perform |
| Apr-04-23 | Initiated | Piper Sandler | Overweight |
| Feb-15-23 | Downgrade | Jefferies | Buy → Hold |
| Aug-01-22 | Downgrade | Truist | Buy → Hold |
| Jul-27-22 | Upgrade | Jefferies | Hold → Buy |
| Jun-27-22 | Resumed | Canaccord Genuity | Buy |
| Feb-02-22 | Initiated | Canaccord Genuity | Buy |
| Jan-28-22 | Initiated | Truist | Buy |
| Aug-05-20 | Downgrade | Jefferies | Buy → Hold |
| Sep-24-19 | Initiated | Jefferies | Buy |
| Sep-06-19 | Initiated | H.C. Wainwright | Buy |
| Feb-04-19 | Downgrade | B. Riley FBR | Buy → Neutral |
| Aug-10-18 | Reiterated | Stifel | Hold |
| May-31-18 | Downgrade | Stifel | Buy → Hold |
| Mar-09-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Aug-31-17 | Initiated | Stifel | Buy |
| Feb-02-17 | Initiated | Ladenburg Thalmann | Buy |
| Apr-21-15 | Initiated | FBR Capital | Outperform |
| Jan-13-14 | Downgrade | Stifel | Buy → Hold |
| Aug-09-13 | Downgrade | Janney | Buy → Neutral |
| Aug-09-13 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Feb-21-12 | Reiterated | JMP Securities | Mkt Outperform |
| Jan-06-10 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jul-17-08 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jun-21-07 | Upgrade | Punk, Ziegel & Co | Mkt Perform → Accumulate |
View All
Corcept Therapeutics Inc Stock (CORT) Latest News
Deadline Alert: Corcept Therapeutics Incorporated (CORT) - GlobeNewswire
Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
CORT 1-WEEK DEADLINE ALERT: Hagens Berman Alerts Corcept - GlobeNewswire
CORT 1-WEEK DEADLINE ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Approaching April 21st Lead Plaintiff Deadline in Securities Fraud Class Action Over Relacorilant Failure - GlobeNewswire Inc.
Portnoy Law Firm Announces Class Action on Behalf of Corcept Therapeutics Incorporated Investors - GlobeNewswire
Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock DeclineInvestors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC - ACCESS Newswire
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
CORT ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Approaching April 21st Lead Plaintiff Deadline in Securities Fraud Class Action Over Relacorilant Failure - The Malaysian Reserve
Press releases provided by CNW - Techaeris
Corcept Therapeutics (CORT) climbs 19.7% as Lifyorli gets FDA OK - MSN
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit - PR Newswire
Corcept Leaders Sued Over Drug-Approval Remarks, Stock Sales - Bloomberg Law News
Bragar Eagel & Squire, P.C. Reminds Investors that a Class - GlobeNewswire
Corcept Therapeutics Incorporated Sued for Securities Law - GlobeNewswire
CORT SHAREHOLDER ACTION ALERT: Kaplan Fox Alerts Investors of a Class Action Lawsuit Against Corcept Therapeutics, Inc. (NASDAQ: CORT) and Lead Plaintiff Deadline on April 21, 2026 - NewMediaWire
Corcept's Lifyorli Plus Nab-Paclitaxel Improves Survival in Platinum-Resistant Ovarian Cancer - National Today
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
How The Corcept Therapeutics (CORT) Investment Story Is Shifting After Legal And Regulatory Updates - Yahoo Finance
Corcept’s Lifyorli shows 35% reduction in death risk for ovarian cancer - Investing.com Australia
DEADLINE ALERT: Kaplan Fox Alerts Investors to a Securities Class Action Against Corcept Therapeutics, Inc. (NASDAQ: CORT)Deadline is April 21, 2026 - NewMediaWire
FinancialContentDEADLINE ALERT: Kaplan Fox Alerts Investors to a Securities Class Action Against Corcept Therapeutics, Inc. (NASDAQ: CORT)Deadline is April 21, 2026 - FinancialContent
Corcept Therapeutics (CORT) Unveils Promising Survival Data from ROSELLA Trial - GuruFocus
Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli™ (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in Patients with Platinum-Resistant Ovarian Cancer - Business Wire
1 Healthcare Stock with Promising Prospects and 2 Facing Headwinds - Yahoo Finance
INVESTOR DEADLINE: Corcept Therapeutics (CORT) Investors - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges Corcept - GlobeNewswire
CORT Shareholder Alert: Corcept Therapeutics Incorporated Securities Class Action Lawsuit ... - Bluefield Daily Telegraph
CORT Shareholder Alert: Corcept Therapeutics Incorporated - GlobeNewswire
Securities Class Action Deadline Against Corcept Therapeutics, Inc. (NASDAQ: CORT)Contact Kaplan Fox Before April 21, 2026 - FinancialContent
Analysts Offer Insights on Healthcare Companies: Autolus Therapeutics (AUTL) and Corcept Therapeutics (CORT) - The Globe and Mail
CORT Stock Price, Quote & Chart | CORCEPT THERAPEUTICS INC (NASDAQ:CORT) - ChartMill
CORT FINAL DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Corcept Therapeutics ... - Caledonian Record
Deadline Alert: Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit - GlobeNewswire
Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire
CORT DEADLINE ALERT: Kaplan Fox Reminds Investors of a Class Action Lawsuit Against Corcept Therapeutics, Inc. (NASDAQ: CORT) and Lead Plaintiff Deadline on April 21, 2026 - NewMediaWire
CORT Investors Have Opportunity to Lead Corcept - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming DeadlinesCORT - PR Newswire
Corcept therapeutics officer Guyer sells $819k in shares By Investing.com - Investing.com UK
Corcept (NASDAQ: CORT) CDO sells 20,000 shares after option exercise - Stock Titan
Corcept (CORT) director Wilson reports 5,000-share stock gift via trust - Stock Titan
CORT ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Inve - The National Law Review
CORT ALERT: Hagens Berman Alerts Corcept Therapeutics - GlobeNewswire
CORT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Corcept Therapeutics Incorporated Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
CORT INVESTOR ALERT: Investors of Corcept Therapeutics, Inc. (NASDAQ: CORT) Are Encouraged to Contact Kaplan Fox Before Lead Plaintiff Deadline on April 21, 2026 - FinancialContent
Corcept Therapeutics Inc (NASDAQ:CORT): An Affordable Growth Stock Built on a Strong Foundation - ChartMill
Corcept Therapeutics Incorporated Securities Fraud Class - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines – CORT - ChartMill
Corcept (CORT) Class Action Alleges Misstatements on FDA Data ConcernsHagens Berman - ChartMill
Insider sells 20,000 CORT shares after option exercise (CORT) - Stock Titan
CORT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Corcept Therapeutics Incorporated Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
CORT Investors Have Opportunity to Lead Corcept Therapeutics Inc - GuruFocus
Corcept Therapeutics Inc Stock (CORT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):